Multiple Myeloma: Biology, Standard Therapy, and Transplant Therapy

Morie A. Gertz, Irene Ghobrial, Jean Luc-Harousseau

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

The understanding of the pathogenesis of multiple myeloma has undergone a major transformation over the past eight years. New insights into the microenvironment of the plasma cell as well as elucidation of signaling pathways that prevent plasma cell apoptosis are leading to rapid new drug development. The introduction of novel agents has led to a significant increase in survival. Combinations of novel agents are expected to provide higher complete response rate with anticipated prolongation of relapse free and overall survival. Autologous and allogeneic stem cell transplantation remains an integral part of therapy further improving the outcomes following induction with novel agents.

Original languageEnglish (US)
Pages (from-to)46-52
Number of pages7
JournalBiology of Blood and Marrow Transplantation
Volume15
Issue number1 SUPPL.
DOIs
StatePublished - Jan 1 2009

    Fingerprint

Keywords

  • Chemotherapy
  • Stem Cell Transplantation
  • genetics
  • multiple myeloma

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this